- Home
- LNZA vs ENGN Comparison
LNZA vs ENGN Comparison
Compare LNZA & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNZA
- ENGN
- Stock Information
- Founded
- LNZA 2005
- ENGN 1999
- Country
- LNZA United States
- ENGN Canada
- Employees
- LNZA N/A
- ENGN N/A
- Industry
- LNZA Major Chemicals
- ENGN
- Sector
- LNZA Industrials
- ENGN
- Exchange
- LNZA Nasdaq
- ENGN Nasdaq
- Market Cap
- LNZA 340.2M
- ENGN 293.1M
- IPO Year
- LNZA N/A
- ENGN N/A
- Fundamental
- Price
- LNZA $1.02
- ENGN $5.83
- Analyst Decision
- LNZA Strong Buy
- ENGN Strong Buy
- Analyst Count
- LNZA 4
- ENGN 8
- Target Price
- LNZA $5.75
- ENGN $30.38
- AVG Volume (30 Days)
- LNZA 607.3K
- ENGN 200.8K
- Earning Date
- LNZA 11-08-2024
- ENGN 12-19-2024
- Dividend Yield
- LNZA N/A
- ENGN N/A
- EPS Growth
- LNZA N/A
- ENGN N/A
- EPS
- LNZA N/A
- ENGN N/A
- Revenue
- LNZA $58,025,000.00
- ENGN N/A
- Revenue This Year
- LNZA N/A
- ENGN N/A
- Revenue Next Year
- LNZA $102.41
- ENGN N/A
- P/E Ratio
- LNZA N/A
- ENGN N/A
- Revenue Growth
- LNZA 7.99
- ENGN N/A
- 52 Week Low
- LNZA $0.84
- ENGN $4.42
- 52 Week High
- LNZA $5.73
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- LNZA 43.72
- ENGN 26.75
- Support Level
- LNZA $0.84
- ENGN $5.68
- Resistance Level
- LNZA $1.04
- ENGN $6.55
- Average True Range (ATR)
- LNZA 0.09
- ENGN 0.69
- MACD
- LNZA 0.02
- ENGN -0.24
- Stochastic Oscillator
- LNZA 51.43
- ENGN 6.99
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a nature-based carbon refining company that transforms waste carbon into the chemical building blocks for consumer goods such as sustainable fuels, fabrics, and packaging that people use in their daily lives. The company's goal is to reduce the need for virgin fossil fuels by challenging and striving to change the way the world uses carbon.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.